fda semaglutide warning november 2025 Decisions Expected: - Prime Therapeutics July 29, 2024: FDA issued

Retrieved from McMurtry, C

The Ozempic lawsuit continues to gain attention as increasing numbers of consumers report severe side effects from GLP-1 receptor agonists, including Ozempic and Wegovy, which doctors frequently prescribe for managing obesity and diabetes

Some common brand names for Semaglutide include Ozempic and Rybelsus

Our medical team can help you understand your condition, provide proper diagnostic testing, and develop a comprehensive treatment plan tailored to your individual health needs

People using Semaglutide (the active ingredient in Ozempic) have lost an average of about 15% of their body weight over roughly 68 weeks in clinical research